A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan

<div>Ame55 binding to EGFR. (a) Analysis of cetuximab and purified Ame55 antibody with 10% SDS-PAGE (reducing) gel. (b) Specific binding of Ame55 and cetuximab to different proteins (10 <i>μ</i>g/mL) with ELISA. (c) Binding of cetuximab, Ame55, and nimotuzumab (50 <i>μ</i>g/mL each) in CHO (no EGFR), Lovo (moderately expressed EGFR), and A431 (highly expressed EGFR) cell surfaces.</div>

Journal of Immunology Research

fig1

Figure 1

Figure 1: A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan 